Nyrada, Inc.ASX: NYR

Nyrada Receives Positive FDA Feedback

· Issued by Nyrada, Inc. via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Nyrada, Inc. has received positive feedback from the US FDA regarding its pre-Investigational New Drug meeting for Xolatryp®, its lead candidate aimed at reducing heart attack injury. The FDA's response supports Nyrada's proposed development pathway, indicating no major issues were identified.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/nyrada-receives-positive-fda-feedback

Release

Page 1 Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818 13 October 2026 Sydney, Australia Nyrada Receives Positive FDA Feedback Highlights: • Nyrada has received written feedback from the US Food and Drug Administration (FDA) in response to its...

Nyrada, Inc. on 6ix

Earlier from Nyrada

All Nyrada news releases